ESMO2018 演題レポート Munich, Germany 19 Oct - 23 Oct 2018

2018年10月19日~23日にドイツ・ミュンヘンで開催された 2018年 欧州臨床腫瘍学会学術集会(ESMO 2018 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。

Live Short Cuts


Proffered Paper Session


Durable clinical benefit with nivolumab plus low-dose ipilimumab as first-line in microsatellite instability ?high/mismatch repair deficient metastatic colorectal cancer.

Heinz-Josef J. Lenz, et al.


Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from cohort 2 of MODUL ? a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.

Axel Grothey, et al.


TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).

Chiara Cremolini, et al.


TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer.

Hendrik-Tobias Arkenau, et al.


Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC).

Michael J. Pishvaian, et al.


A randomized multicentered phase 2 study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment.

Shu K. Qin, et al.


Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study.

Minetta C. Liu, et al.


Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA).

Daisuke Sakai, et al.

Poster Discussion Session


Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.

Milind Jovle, et al.


Efficacy and quality of life in VOLFI trial: mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): a randomized phase II trial of the AIO (AIO-KRK-0109).

Michael Geissler, et al.


Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon2 metastatic colorectal cancer.

Hiroya Taniguchi, et al.


A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.

Taroh Sato, et al.


Enteral nutrition improves nutritional status, treatment tolerance and outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy: results of a prospective, randomized, controlled, multicenter trial (NCT02399306).

Tao Li, et al.

Poster Display Session


Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer.

Toshiki Masuishi, et al.


Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.

Takayuki Yoshino, et al.


A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).

Keisho Chin, et al.

Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B.

Satoshi Yuki, et al.

by European Society for Medical Oncology

by European Society for Medical Oncology

by European Society for Medical Oncology

by European Society for Medical Oncology